Polycystic kidney disease (PKD) is characterized by the growth of numerous fluid filled cysts in the kidneys. When cysts form in the kidneys, they are filled with fluid. PKD cysts can profoundly enlarge the kidneys while replacing much of the normal structure, resulting in reduced renal function and leading to renal failure. Autosomal dominant polycystic kidney disease (ADPKD) is a hereditary disease that occurs in one out of 1000 humans. PKD and its causes are being dissected through studies of human populations and through the use of animal models. Mouse models in particular have made a substantial contribution to our understanding of the gene pathways involved in the pathogenesis and the nature of signaling molecules that act in a tissue-specific manner at critical stages of cyst development. PKD has a number of characteristics that make it uniquely challenging for the development of therapies to slowdown disease progression. This review provides current understanding of the etiopathology, pathways involved and therapeutic targets of PKDs.

**Implication for health policy/practice/research/medical education:**
Polycystic kidney disease (PKD) is characterized by the growth of numerous fluid filled cysts in the kidneys. PKD cysts can profoundly enlarge the kidneys while replacing much of the normal structure, resulting in reduced renal function and leading to end-stage renal disease (ESRD). Given that currently, there are no active effective treatments for PKD, other than renal replacement therapy when indicated, the focus of scientists and clinicians ought for the development of therapies to slowdown disease progression. This review focuses on the current understanding of the pathways and therapeutic targets in PKD.

*Please cite this paper as:* Bhaskar LVKS, Elumalai R, Periasamy S. Pathways, perspectives and pursuits in polycystic kidney disease. J Nephropharmacol. 2016;5(1):41-48.
the nephron with prevalence to the collecting duct (CD) (6,7) and in ARPKD renal cyst formation is virtually restricted to the CD (6,8,9). Several lines of evidence demonstrate that the mechanical stress arising from variations in tubular flow or tubular composition in CD cells elevate [Ca$^{2+}$] (10-12). These impaired mechanosensitive [Ca$^{2+}$] responses, observed for both cultured ADPKD (13) and ARPKD cells (14-16), indicating that the disrupted [Ca$^{2+}$], signaling plays a fundamental role in cystogenesis. Several studies have provided compelling evidence for the function of polycystin-1 (PC-1) and polycystin-2 (PC-2) proteins. Polycystin-2 can act as a calcium-ion-permeable cation channel, and that polycystin-1 may be involved in regulating/localizing this channel, and play a role in regulating calcium homeostasis. A disruption in intracellular calcium homeostasis seems likely to result in many cellular abnormalities associated with cystogenesis in ADPKD. Further, polycystin 1 and 2 appears to be a member of a superfamily of proteins involved in regulation of renal epithelial cell growth. In the kidney, PC-2 like PC-1 is expressed in all nephron segments, with the possible exception of the thin limbs, but is absent from glomeruli (17).

Thus, ADPKD has two disease loci, PKD1 and PKD2, the loss of both copies disrupts this cascade and causes hyperplasia of a given cell resulting in a cyst. The mutations of PKD1 gene located on 16p13.3 are responsible for 85% of cases, remaining 15% by the mutations of PKD2 gene which is located on the chromosome 4q21-23 (18,19). In elderly patients, the PKD2 mutations are more prevalent than the PKD1. Forty percent of PKD patients were shown the progression of ESRD by the age 63 years have disease linked to PKD2 (20,21). However, among the ADPKD patients the mutations of PKD1 and PKD2 produce the identical renal and extra renal manifestations (22).

ARPKD is a recessive disorder, studies using spontaneously aroused PCK rat model and the method of positional cloning in human ARPKD families indicated that ARPKD is caused by mutations in PKHD1 gene that localized to chromosome region 6p12. The PKHD1 gene encodes the protein fibrocystin or polycystin, which homologous to the proteins of PKD1 and PKD2, has been found in the primary cilium and basal body of renal and bile duct epithelium (23). The PKHD1 has expressed at high levels in the human foetal and adult kidneys, but the lower level expression was detected in the liver and pancreas. So far, more than 300 mutations was documented in PKHD1; among these the truncating mutations exhibits most severe cases, are often leads prenatal or neonatal death (24,25). As majority of mutations being rare variants and one third of these mutations seen in single families, only 10%-20% of ARPKD cases are associated common mutations of PKHD1 gene.

Pathways in polycystic kidney disease

Although, cellular changes and mechanisms involved in initial stages of cyst formation might differ between ADPKD and ARPKD, the pathogenetic mechanisms become increasingly similar as the disease progresses and involve common pathways (26,27). Once the cysts are formed, further the abnormal cells enforce continuous stress on the surrounding tissues, resulting local injury, which is probably accompanied by synthesis of growth factors and cytokines, triggering additional cyst formation (28). Furthermore, the development and enlargement of cysts in ADPKD requires tubular cell proliferation, extracellular matrix abnormalities and trans-epithelial fluid secretion. Many signaling pathways and transcription factors control the development and growth of polycystic kidneys (29).

Fluid flow-induced bending of the primary cilia causes calcium influx into the cell through PC2 channels, allowing for release of calcium from intracellular stores. Calcium influx into cells modulates the activities of calcium-binding proteins (30,31) that can regulate signal transduction pathways leading to changes in gene expression and the control of cell growth and differentiation (32,33). The reduced calcium caused by mutation of PKD1 or PKD2 can inhibit adenyl cyclase 6 leading to increased cyclic adenosine monophosphate (cAMP). Cyclic AMP may have a central role in cyst growth by stimulating both fluid secretion and cell proliferation (34,35). It has been demonstrated that cAMP inhibits the proliferation of normal renal epithelial cells. In contrast, cAMP promotes the proliferation of cells derived from PKD patients (34). Low intracellular calcium causes cAMP elevation, which in turn stimulates B-Raf, mitogen-associated/extracellular-regulated kinase (MEK) and extracellular signal-regulated kinase (ERK) in cystic kidney cells but not in normal kidney cells. In normal kidney cells, B-Raf is repressed by Akt (protein kinase B) in a phosphoinositide-3 kinase (PI3K) and calcium-dependent manner, but in cystic kidney and calcium-restricted cells, Akt activity is reduced, allowing for activation of B-Raf by cAMP (36). Abnormalities in a number of other intra cellular signaling pathways not regulated by Ca$^{2+}$ or cAMP have also been reported. These include mammalian target of rapamycin (mTOR) (37), PI3-kinase (38,39), cystic fibrosis transduction regulator (CFTR) (40), Jak2-STAT1/3 (41), NFAT (nuclear factor of activated T cells) (42), and NF-kB (nuclear factor kappa B) signaling (43).

The phosphoinositide 3 kinase (PI 3-kinase) signaling pathway is an excellent candidate for regulation of epithelial tubule formation. It was demonstrated that PI3-kinase plays an important role in the regulation of kidney tubule branching morphogenesis during development (44). PC-1 can induce resistance to apoptosis through the phosphatidylinositol 3-kinase/Akt signaling pathway (38,39). PC-1 can also favor cell migration by regulating PI3-kinase-dependent cytoskeletal rearrangements (38). Another downstream signaling target that is regulated by changes in PI 3-kinase activity levels is the mammalian target for
rapamycin (mTOR). There is overwhelming evidence that the PC-1 controls the mTOR pathway and regulates cell size in a Tsc2-dependent manner, by inhibiting the ERK-mediated phosphorylation of tuberin (45). Cyst growth in ADPKD involves proliferation of the cyst lining cells and fluid secretion into the cyst lumen due to transepithelial secretion of chloride subsequent to an increase in cAMP mediated by cystic fibrosis transmembrane conductance regulator (CFTR) (46). This suggests that inhibitors of the CFTR Cl-channel might retard cyst growth. However, expression of CFTR protein in PKD cysts is highly heterogeneous and it is therefore postulated that additional ion channels other than CFTR might also attribute to electrolyte secretion that leads to cyst growth. Calcium-dependent chloride channels, that are activated through stimulation of Gq-coupled purinergic receptors (P2YR), are potential candidates for the mechanisms of the secretion (47). Further, epidermal growth factor (EGF) signaling play a major role in renal electrolyte homeostasis and cyst growth in both ADPKD and ARPKD through cellular proliferation of incompletely differentiated epithelial cells and accumulation of fluid within the cysts (48). Since EGF and its related growth factors regulate the epithelial Na⁺ channel activity, it is possible that ENaC inhibition facilitates cyst formation in PKD (49). A coordinated interaction between ENaC and CFTR was found in disease processes associated with dysfunctional CFTR (50,51). Expression of polycystin-1 activates the JAK-STAT pathway in a process that requires polycystin-2, thus upregulating p21 (waf1) and inducing cell cycle arrest in G0/G1. Mouse embryos lacking Pkd1 have defective STAT1 phosphorylation and p21 (waf1) induction indicating that the polycystin-1/2 complex is to regulate the JAK/STAT pathway. Further, mutations that disrupt polycystin-1/2 binding prevent activation of the JAK-STAT pathway (41). Further support for PC1 signaling through G-proteins comes from PC1 activation of phospholipase C (PLC) mediated by the Gaq and the subsequent activation of the calcineurin/nuclear factor of activated T-cells (NFAT) pathway. Signaling through this pathway also connects the function of polycystins as regulators of intracellular calcium levels. Exogenous expression of the PC1 C tail domain results in an increase in calcium level in a reaction requiring PLC β. This intracellular increase in calcium leads to the activation of calcineurin, a serine–threonine phosphatase that dephosphorylates NFAT. Activated NFAT translocates to the nucleus and regulates target genes at composite NFAT/AP-1 elements. In addition to the evidence for PC1 mediating NFAT activation, NFAT is co-expressed with PC1 in renal tubular epithelial cells of developing and adult mice, proposing that NFAT and PC1 may work together in a pathway (42). HEK293 cells silenced for PKHD1 showed a higher PI3K/Akt activity, selective inhibition of PI3K/Akt using LY294002 or wortmannin in these cells increased NF-κB activity (43).

### Therapeutic approaches in polycystic kidney disease

The increased understanding of the molecular mechanisms of PKD has provided a number of targets for therapeutic intervention. Molecular pathogenesis of cystogenesis and cyst progression are the targets of current therapy (Table 1). Many signaling pathways and transcription factors control the cystogenesis and cyst progression of polycystic kidneys. Owing to functional redundancy, reciprocal reinforcement and feedback loops these pathways should be considered as a part of network. Cells lacking PC1 and PC2 proteins show decreased levels of calcium that trigger adenyl cyclase and leading to increased levels of cAMP

### Table 1. Pathway targets and therapeutic approaches used in the treatment of PKD

| Treatment target                                      | Possible therapy                                      | Reference |
|-------------------------------------------------------|-------------------------------------------------------|-----------|
| Increased apoptosis                                    | Roscovitine (Seliciclib, CYC202)                      | (52,53)   |
| CDK                                                   | Caspase inhibitors (IDN-8050)                         | (54)      |
| Increased proliferation                               |                                                       |           |
| cAMP                                                  | Vasopressin V2-receptor antagonists                   | (55,56)   |
| mTORC1 and 2                                          | mTOR inhibitors                                      | (57,58)   |
| Renin-angiotension system                             | ACE inhibitors/ARBs                                  | (59-61)   |
| Tyrosine kinases                                       | EGFR tyrosine kinase inhibitor                        | (62,63)   |
| Transcription factors                                  | PPAR-γ agonist                                       | (64,65)   |
| Abnormal extra cellular matrix metabolism             |                                                       |           |
| Increased collagen expression                         | PPAR-γ agonist                                       | (66)      |
| Increased metalloproteinases activity                 | MMP inhibitor (batimastat)                            | (67)      |
| Abnormal fluid secretion                              |                                                       |           |
| cAMP                                                  | Vasopressin V2-receptor antagonists                   | (68,69)   |
| CFTR                                                  | Thiazolidinone and glycine hydrazide analogs         | (46,70,71)|
| Cilia                                                 | TRPC and TRPP2 channel blockers                      | (72)      |
| Calcium influx                                        | TNF-α inhibitors                                     | (73)      |
| Inflammation                                          |                                                       |           |
| Polycystin-1/polycystin-2                             | Inhibitors of PI3K (LY294002 and wortmannin)         | (74)      |

Abbreviations: CDK, Cyclin-dependent kinase; cAMP, cyclic adenosine monophosphate; CFTR, cystic fibrosis transduction regulator; PKD, polycystic kidney disease.
The central role of cAMP in the pathogenesis of PKD and the ability to hormonally modulate cAMP in a cell-specific manner provide opportunities for such strategies in PKD. It is very important to note that vasopressin V2-receptor and somatostatin SSTR2-receptor signaling utilize cAMP as a second messenger and their signaling increase and decrease cAMP respectively. Hence antagonists of vasopressin V2-receptor (aquaretics) and agonists of somatostatin SSTR2-receptor were used to achieve the desired inhibition of intracellular aAMP. Two important aquaretics OPC-31260 and tolvaptan showed reduction in cAMP levels, slowing cystogenesis, and renal enlargement and dysfunction in murine models (76,77). Further, these aquaretics have been approved for the treatment of ADPKD in Japan (78). The somatostatin analogue, octreotide, was found to be effective in slowing progression in liver and kidney cystic disease in a rat model of PKD. Inhibition of cAMP levels and delayed cyst growth in vitro by octreotide provided further scope for the octreotide in the treatment of PKDs (55). A patient with ADPKD receiving octreotide showed simultaneous reduction in hepatic, kidney and breast cystic volume with preservation of renal function (79). Treatment with octreotide long-acting release in Japanese ADPKD patients showed that Octreotide is safe and effective drug in controlling total kidney volume (TKV) and total liver volume (TLV) (80). As cAMP elevation in cystic kidney cells stimulates B-Raf, MEK and ERK (81), their inhibitors were tested for their action in retarding the progression of PKD (82). Administration of an oral MEK inhibitor, PD184352, inhibited renal cyst enlargement in pcy mice by suppressing ERK (83). In contrast to this MEK1/2 inhibitor U0126 had no protective effect in the acute perinatal Pkd1 model of ADPKD (84). Further, PLX5668, a novel selective small molecule inhibitor of Raf kinases attenuated cyst enlargement in vitro and failed to improve kidney function in a rat model of ADPKD (85). Thus, the therapeutic value of blocking MAPK/ERK signaling pathway in PKD is still controversial. Inhibition of EGF signaling by a EGFR tyrosine kinase inhibitor (EKI-785) slowed the progression of PKD and reduced mortality in rat model (63). Further, EKI-785 and EKB-569 attenuated the development of PKD in Han:SPRD rats (86). In contrast to this over expression and mislocalization of EGFR are not detected at the apical membrane of cystic cells in PCK rats (87), question the potential therapeutic benefits of EGFR tyrosine kinase inhibitors in treating the PKD. Previous studies demonstrated an increased mTOR signaling (37) in murine models and human ADPKD, while mTOR inhibitors reverse ADPKD progression (88). Further, sirolimus (rapamycin) prevented aberrant activation of mTOR in epithelial cells lining the cysts and decreased polycystic liver volume, in sirolimus-treated transplant recipient ADPKD patients (89). While in one study with everolimus, cyst volume was blunted, renal functional loss was unchanged at the expense of greater side effects (90). In general previously conducted clinical trials could not demonstrate any clinically relevant effect of mTOR inhibition on cyst growth or renal function. However, a recently published randomized controlled pilot study demonstrated a significant increase in 125I-iothalamate (iGFR) in ADPKD patients receiving low-dose rapamycin compared with those receiving standard care, without a significant effect on total kidney volume after 12 months (91). As it is not possible to find a treatment plan that satisfy all desired dose levels simultaneously, some compromise between under dosing the target organ and overdosing the surrounding organs has to be found. Treating ADPKD by combining low dose mTOR inhibitors with non-mTOR based treatments is an effective strategy that would maximize efficiency and prevent adverse side effects (92). A study in pkd1 mice demonstrated dose dependent effects serolimus on mTOR signalling and showed that the conventional doses in man (blood concentrations ~3 µg l−1) are ineffective in slowing cystogenesis (93). Capitalizing on the observation that PCKD cells express high levels of folate receptors, folate-conjugated rapamycin has been used as a novel approach to improve direct drug delivery to renal epithelial cells for effectively limiting cyst growth and reducing side effects (94).

Increased renal vascular resistance exhibited by hypertensive patients is the first demonstration of the involvement of RAAS in modulation of hypertension in ADPKD (95). The RAAS contributes to hypertension in ADPKD, but may also independently accelerate renal cyst growth. Presence of RAAS components (AGT, ACE, ANG II and angiotensin II type I receptor) within cysts and tubules and activation of RAAS during cyst expansion in ADPKD has also been demonstrated (96). Angiotensin II receptor blockers (ARBs) increased renal blood flow in ADPKD, while having an acceptable side effect profile (60,97,98). Several studies in animal models of PKD have shown that ACE inhibitors decreased cyst formation and improved renal function (99,100). The studies on ACE inhibitors in ADPKD are inconclusive because they have used small numbers of patients for shorter periods of time (101-105).

Conclusion
Till date, the treatment options for PKD have been limited to kidney replacement therapy by dialysis or transplantation. Understanding of molecular mechanisms underlying ADPKD pathogenesis led to the development of pathway-based therapies for the polycystic kidney. At each step in the pathway, a new treatment could be developed, but complete inhibition of PKD progression may require a combination of the various treatments.

Authors’ contribution
LVKSB: Conception, design, drafting the article and final approval of manuscript. RE and SP: Critical revising of im-
portant intellectual content, final approval of manuscript.

Conflicts of interest
The authors declared no competing interests.

Ethical considerations
Ethical issues (including plagiarism, data fabrication, double publication) have been completely observed by the authors.

Funding/Support
None.

References
1. Gabow PA. Autosomal dominant polycystic kidney disease. Am J Kidney Dis. 1993;22:511-2.
2. Pei Y. Practical genetics for autosomal dominant polycystic kidney disease. Nephron Clin Pract. 2011;118:c19-30.
3. Zerres K, Rudnik-Schoneborn S, Steinkamm C, Becker J, Mucher G. Autosomal recessive polycystic kidney disease. J Mol Med (Berl). 1998;76:303-9.
4. Yoder BK, Hou X, Guay-Woodford LM. The polycystic kidney disease proteins, polycystin-1, polycystin-2, polaris, and cystin, are co-localized in renal cilia. J Am Soc Nephrol. 2002;13:2508-16.
5. Zerres K, Ortiz Bruchle N. [Cystic kidney diseases]. Der Internist. 2012;53:419-21.
6. Harris PC, Torres VE. Polycystic kidney disease. Annu Rev Med. 2009;60:321-37.
7. Harris VE. Treatment of polycystic liver disease: one size does not fit all. Am J Kidney Dis. 2007;49:725-8.
8. Bell PD, Fitzgibbon W, Sas K, Stenbit AE, Amria M, Houston A, et al. Loss of primary cilia upregulates renal hypertrophic signaling and promotes cystogenesis. J Am Soc Nephrol. 2011;22:839-48.
9. Siroky BJ, Guay-Woodford LM. Renal cystic disease: the role of the primary cilium/centrosome complex in pathogenesis. Advances in chronic kidney disease. 2006;13:131-7.
10. Tomlin V, Mamenko M, Zaika O, Pochynyuk O. Role of renal TRP channels in physiology and pathology. Semin Immunopathol. 2015 Sep 18.
11. Zaika O, Mamenko M, Berrout J, Boukelmoune N, O’Neil RG, Pochynyuk O. TRPV4 dysfunction promotes renal cystogenesis in autosomal recessive polycystic kidney disease. J Am Soc Nephrol. 2013;24:604-16.
12. Pochynyuk O, Zaika O, O’Neil RG, Mamenko M. Novel insights into TRPV4 function in the kidney. Pflügers Arch. 2013;465:177-86.
13. Kuo JY, DesRochers TM, Kimmerling EP, Nguyen L, Ehrlich BE, Kaplan DL. Cyst formation following disruption of intracellular calcium signaling. Proc Natl Acad Sci U S A. 2014;111:14283-8.
14. Hu B, He X, Li A, Qiu Q, Li C, Liang D, et al. Cystogenesis in ARPKD results from increased apoptosis in collecting duct epithelial cells of Pkhd1 mutant kidneys. Exp Cell Res. 2011;317:173-87.
15. Hovater MB, Olteanu D, Hanson EL, Cheng NL, Siroky B, Finha A, et al. Loss of apical monocilia on collecting duct principal cells impairs ATP secretion across the apical cell surface and ATP-dependent and flow-induced calcium signals. Purinergic Signal. 2008;4:155-70.
16. Nagano J, Kitamura K, Hujer KM, Ward CJ, Bram RJ, Hopfer U, et al. Fibrocystin interacts with CAML, a protein involved in Ca2+ signaling. Biochem Biophys Res Commun. 2005;338:880-9.
17. Markowitz GS, Cai Y, Li L, Wu G, Ward LC, Somlo S, et al. Polycystin-2 expression is developmentally regulated. J Am Physiol. 1999;277:F17-25.
18. Vazifehmand R, Rossetti S, Saber S, Khorshid HR, Harris PC. Molecular analysis of a consanguineous Iranian polycystic kidney disease family identifies a PKD2 mutation that aids diagnostics. BMC Nephrol. 2013;14:190.
19. Harris PC, Rossetti S. Molecular diagnostics for autosomal dominant polycystic kidney disease. Nature reviews Nephrology. 2010;6:197-206.
20. Torra R, Badenas C, Perez-Oller L, Luis J, Millan S, Nicolau C, et al. Increased prevalence of polycystic kidney disease type 2 among elderly polycystic patients. Am J Kidney Dis. 2000;36:728-34.
21. Pei Y, He N, Wang K, Kasenda M, Paterson AD, Chan G, et al. A spectrum of mutations in the polycystic kidney disease-2 (PKD2) gene from eight Canadian kindreds. J Am Soc Nephrol. 1998;9:1853-60.
22. Hateboer N, v Dijk MA, Bogdanova N, Coto E, Saggard-Malik AK, San Millan JL, et al. Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group. Lancet. 1999;353:103-7.
23. Zhang MZ, Mai W, Li C, Cho SY, Hao C, Moeckel G, et al. PKHD1 protein encoded by the gene for autosomal recessive polycystic kidney disease associates with basal bodies and primary cilia in renal epithelial cells. Proc Natl Acad Sci U S A. 2004;101:2311-6.
24. Bergmann C, Kupper F, Schmitt CP, Vester U, Neuhaus TJ, Senderek J, et al. Multi-exon deletions of the PKHD1 gene cause autosomal recessive polycystic kidney disease associates with basal bodies and primary cilia in renal epithelial cells. Proc Natl Acad Sci U S A. 2004;101:2311-6.
25. Sharp AM, Messiaen LM, Page G, Antignac C, Gubler MC, Onuchic LF, et al. Comprehensive genomic analysis of PKHD1 mutations in ARPKD cohorts. J Med Genet. 2005;42:e63.
26. Chapin HC, Caplan MJ. The cell biology of polycystic kidney disease. J Cell Biol. 2010;191:701-10.
27. Terryn S, Ho A, Beaufays R, Devuyst O. Fluid transport and cystogenesis in autosomal dominant polycystic kidney disease. Biochim Biophys Acta. 2011;1812:1314-21.
loss of the suppressor of cytokine signaling-1 (SOCS-1). Proc Natl Acad Sci U S A. 2002;99:943-8.

29. Chapin HC, Rajendran V, Caplan MJ. Polycystin-1 surface localization is stimulated by polycystin-2 and cleavage at the G protein-coupled receptor proteolytic site. Mol Biol Cell. 2010;21:4338-48.

30. Carafoli E. Calcium signaling: a tale for all seasons. Proc Natl Acad Sci U S A. 2002;99:1115-22.

31. Haeseeler F, Imanishi Y, Sokal I, Filipek S, Palczewski K. Calcium-binding proteins: intracellular sensors from the calmodulin superfamily. Biochem Biophys Res Commun. 2002;290:615-23.

32. Munaron L. Calcium signalling and control of cell proliferation by tyrosine kinase receptors (review). Int J Mol Med. 2002;10:671-6.

33. McKinsey TA, Zhang CL, Olson EN. MEF2: a calcium-dependent regulator of cell division, differentiation and death. Trends Biochem Sci. 2002;27:40-7.

34. Yamaguchi T, Pelling JC, Ramaswamy NT, Eppler JW, Wallace DP, Nagao S, et al. CAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway. Kidney Int. 2000;57:1460-71.

35. Calvet JP, Grantham JJ. The genetics and physiology of polycystic kidney disease. Semin Nephrol. 2001;21:107-23.

36. Yamaguchi T, Wallace DP, Magenheimer BS, Hempson SJ, Grantham JJ, Calvet JP. Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype. J Biol Chem. 2004;279:40419-30.

37. Shillingford JM, Murcia NS, Larson CH, Low SH, Hedgepeth R, Brown N, et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci U S A. 2006;103:5466-71.

38. Boca M, D’Amato L, Distefano G, Polishchuk RS, Germino GG, Boletta A. Polycystin-1 induces cell migration by regulating phosphatidylinositol 3-kinase-dependent cytoskeletal rearrangements and GSK3beta-dependent cell mechanical adhesion. Mol Biol Cell. 2007;18:4050-61.

39. Boca M, Distefano G, Qian F, Bhunia AK, Germino GG, Boletta A. Polycystin-1 induces resistance to apoptosis through the phosphatidylinositol 3-kinase/Akt signaling pathway. J Am Soc Nephrol. 2006;17:637-47.

40. Nakanishi K, Sweeney WE, Jr., Macrae Dell K, Cotton CU, Ayner ED. Role of CFTR in autosomal recessive polycystic kidney disease. J Am Soc Nephrol. 2001;12:719-25.

41. Bhunia AK, Piontek K, Boletta A, Liu L, Qian F, Xu PN, et al. PKD1 induces p21(raf1) and regulation of the cell cycle via direct activation of the JAK-STAT signaling pathway in a process requiring PKD2. Cell. 2002;109:157-68.

42. Puri S, Magenheimer BS, Masera RL, Ryan EM, Zien CA, Walker DD, et al. Polycystin-1 activates the calcineurin/NFAT (nuclear factor of activated T-cells) signaling pathway. J Biol Chem. 2004;279:55455-64.

43. Sun L, Wang S, Hu C, Zhang X. Down-regulation of PKHD1 induces cell apoptosis through PI3K and NF-kappaB pathways. Exp Cell Res. 2011;317:932-40.

44. Tang MJ, Cai Y, Tsai SJ, Wang YK, Dressler GR. Ureteric bud outgrowth in response to RET activation is mediated by phosphatidylinositol 3-kinase. Dev Biol. 2002;243:128-36.

45. Distefano G, Boca M, Rowe I, Wodarczyk C, Ma L, Piontek KB, et al. Polycystin-1 regulates extracellular signal-regulated kinase-dependent phosphorylation of tuberin to control cell size through mTOR and its downstream effectors S6K and 4EBP1. Mol Cell Biol. 2009;29:2359-71.

46. Yang B, Sonawane ND, Zhao D, Somlo S, Verkman AS. Small-molecule CFTR inhibitors slow cyst growth in polycystic kidney disease. J Am Soc Nephrol. 2008;19:1300-10.

47. Buchholz B, Teschemacher B, Schley G, Schillers H, Eckardt KU. Formation of cysts by principal-like MDCK cells depends on the synergy of cAMP- and ATP-mediated fluid secretion. J Mol Med (Berl). 2011;89:251-61.

48. Melenhorst WB, Mulder GM, Xi Q, Hoenderop JG, Kimura K, Eguchi S, et al. Epidermal growth factor receptor signaling in the kidney: key roles in physiology and disease. Hypertension. 2008;52:987-93.

49. Ma HP, Chou CF, Wei SP, Eaton DC. Regulation of the epithelial sodium channel by phosphatidylinositides: experiments, implications, and speculations. Pflugers Arch. 2007;455:169-80.

50. Berdiev BK, Shlyonsky VG, Karlson KH, Stanton BA, Ismailov, II. Gating of amiloride-sensitive Na(+) channels: subunit-subunit interactions and inhibition by the cystic fibrosis transmembrane conductance regulator. Biophys J. 2000;78:1881-94.

51. Berdiev BK, Qadri YJ, Benos DJ. Assessment of the CFTR and ENaC association. Mol Biosyst. 2009;5:123-7.

52. MacCallum DE, Melville J, Frame S, Watt K, Anderson S, Gianella-Borradori A, et al. Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of McI-1. Cancer Res. 2005;65:5399-407.

53. McClue SJ, Blake D, Clarke R, Cowan A, Cummings L, Fischer PM, et al. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer. 2002;102:463-8.

54. Tao Y, Kim J, Faubel S, Wu JC, Falk SA, Schrier RW, et al. Caspase inhibition reduces tubular apoptosis and proliferation and slows disease progression in polycystic kidney disease. Proc Natl Acad Sci U S A. 2005;102:6954-9.

55. Masyuk TV, Masyuk AI, Torres VE, Harris PC, Larusso NF. Octreotide inhibits hepatic cystogenesis in a...
regulator inhibitors CFTR(inh)-172 and GlyH-101

60. Torres VE, Abebe KZ, Chapman AB, Schrier RW, Braun WE, Steinman TI, et al. Angiotensin blockade in late autosomal dominant polycystic kidney disease. N Engl J Med. 2014;371:2267-76.

61. Chapman AB, Torres VE, Perrone RD, Steinman TI, Bae KT, Miller JP, et al. The HALT polycystic kidney disease trials: design and implementation. Clin J Am Soc Nephrol. 2010;5:102-9.

62. Sweeney WE Jr, Hamahira K, Sweeney J, Garcia-Gatrell M, Frost P, Avner ED. Combination treatment of PKD utilizing dual inhibition of EGF-receptor activity and ligand bioavailability. Kidney Int. 2003;64:1310-9.

63. Sweeney WE, Chen Y, Nakanishi K, Frost P, Avner ED. Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor. Kidney Int. 2000;57:33-40.

64. Yoshihara D, Kurahashi H, Morita M, Kugita M, Hiki Y, Aukema HM, et al. PPAR-gamma agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease. Am J Physiol Renal Physiol. 2011;300:F465-74.

65. Liu M, Fu L, Liu C, Xiong X, Gao X, Xiao M, et al. DH9, a novel PPARgamma agonist suppresses the proliferation of ADPKD epithelial cells: An association with an inhibition of beta-catenin signaling. Invest New Drugs. 2010;28:783-90.

66. Liu Y, Dai B, Xu C, Fu L, Hua Z, Mei C. Rosiglitazone inhibits transforming growth factor-beta1 mediated fibrogenesis in ADPKD cyst-lining epithelial cells. PloS One. 2011;6:e28915.

67. Obermuller N, Morente N, Kranzlin B, Gretz N, Witzgall R. A possible role for metalloproteinases in renal cyst development. Am J Physiol Renal Physiol. 2001;280:F540-50.

68. Ku E, Nobakht N, Campese VM. Lixivaptan: a novel vasopressin receptor antagonist. Expert Opin Investig Drugs. 2009;18:657-62.

69. Miyazaki T, Fujiki H, Yamamura Y, Nakamura S, Mori T. Tolvaptan, an orally active vasopressin V2-receptor antagonist - pharmacology and clinical trials. Cardiovasc Drug Rev. 2007;25:1-13.

70. Kelly M, Trudel S, Brouillard F, Bouillaud F, Colas J, Nguyen-Khoa T, et al. Cystic fibrosis transmembrane regulator inhibitors CFTR(inh)-172 and GlyH-101 target mitochondrial functions, independently of chloride channel inhibition. J Pharmacol Exp Ther. 2010;333:60-9.

71. Verkman AS, Lukacs GL, Galietta LJ. CFTR chloride channel drug discovery--inhibitors as antidiarrheals and activators for therapy of cystic fibrosis. Curr Pharm Des. 2006;12:2235-47.

72. Mene P, Punzo G, Pirozzi N. TRP channels as therapeutic targets in kidney disease and hypertension. Curr Top Med Chem. 2013;13:386-97.

73. Li X, Magenheimer BS, Xia S, Johnson T, Wallace DP, Calvet JP, et al. A tumor necrosis factor-alpha-mediated pathway promoting autosomal dominant polycystic kidney disease. Nature Med. 2008;14:863-8.

74. Du W, Liu A, Prendergast GC. Activation of the PI3’K-AKT pathway masks the proapoptotic effects of farnesyltransferase inhibitors. Cancer Res. 1999;59:4208-12.

75. Nauli SM, Alenghat FJ, Luo Y, Williams E, Vassilev P, Li X, et al. Polycystins 1 and 2 mediate mechanosensation in the primary cilia of kidney cells. Nature Gen. 2003;33:129-37.

76. Torres VE. Vasopressin antagonists in polycystic kidney disease. Semin Nephrol. 2008;28:306-17.

77. Torres VE. Vasopressin antagonists in polycystic kidney disease. Kidney Intl. 2005;68:2405-18.

78. Torres VE. Vasopressin receptor antagonists, heart failure, and polycystic kidney disease. Ann Rev Med. 2015;66:195-210.

79. Peces R, Cuesta-Lopez E, Peces C, Perez-Duenas V, Vega-Cabrera C, Selgas R. Octreotide reduces hepatic, renal and breast cystic volume in autosomal-dominant polycystic kidney disease. Int Urol Nephrol. 2014;46:565-9.

80. Higashihara E, Nutahara K, Okegawa T, Tanbo M, Mori H, Miyazaki I, et al. Safety study of somatostatin analogue octreotide for autosomal dominant polycystic kidney disease in Japan. Clin Exp Nephrol. 2015;19:746-52.

81. Yamaguchi T, Nagao S, Wallace DP, Belibi FA, Cowley BD, Pelling JC, et al. Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys. Kidney Int. 2003;63:1983-94.

82. Calvet JP. MEK inhibition holds promise for polycystic kidney disease. J Am Soc Nephrol. 2006;17:1498-500.

83. Omori S, Hida M, Fujita H, Takahashi H, Tanimura X, et al. Polycystins 1 and 2 mediate mechanosensation of farnesyltransferase inhibitors. Cancer Res. 2009;69:1520-8.

84. Shibazaki S, Yu Z, Nishio S, Tian X, Thomson RB, Mitobe M, et al. Cyst formation and activation of the extracellular regulated kinase pathway after kidney specific inactivation of Pkd1. Hum Mol Genet. 2008;17:1505-16.

85. Buchholz B, Klankle B, Schley G, Bollag G, Tsai J, Kroening S, et al. The Raf kinase inhibitor PLX5568 slows cyst proliferation in rat polycystic kidney disease
but promotes renal and hepatic fibrosis. Nephrol Dial Transplant. 2011;26:3458-65.

86. Torres VE, Sweeney WE Jr, Wang X, Qian Q, Harris PC, Frost P, et al. EGF receptor tyrosine kinase inhibition attenuates the development of PKD in Han:SPRD rats. Kidney Int. 2003;64:1573-9.

87. Torres VE, Sweeney WE Jr, Wang X, Qian Q, Harris PC, Frost P, et al. Epidermal growth factor receptor tyrosine kinase inhibition is not protective in PCK rats. Kidney Int. 2004;66:1766-73.

88. Wuthrich RP, Kistler AD, Serra AL. Impact of mammalian target of rapamycin inhibition on autosomal-dominant polycystic kidney disease. Transplant Proc. 2010;42:S44-6.

89. Qian Q, Du H, King BF, Kumar S, Dean PG, Cosio FG, et al. Sirolimus reduces polycystic liver volume in ADPKD patients. J Am Soc Nephrol. 2008;19:631-8.

90. Walz G, Budde K, Mannaa M, Nurnberger J, Wanner C, Sommerer C, et al. Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2010;363:830-40.

91. Gorstein J, Sullivan KM, Parvanta I, Begin F. Indicators and methods for cross-sectional surveys of vitamin and mineral status of populations. Micronutrient Initiative (Ottawa) and Centers for Disease Control and Prevention (Atlanta). 2007:29

92. MacCallum C, Johnston SD. Studies on the cryopreservation of common wombat (Vombatus ursinus) spermatozoa. Reprod Fertil Dev. 2005;17:727-32.

93. Albrecht A, Felk A, Pichova I, Naglik JR, Schaller M, de Groot P, et al. Glycosylphosphatidylinositol-anchored proteases of Candida albicans target proteins necessary for both cellular processes and host-pathogen interactions. J Biol Chem. 2006;281:688-94.

94. Bates S, Hughes HB, Munro CA, Thomas WP, MacCallum DM, Bertram G, et al. Outer chain N-glycans are required for cell wall integrity and virulence of Candida albicans. J Biol Chem. 2006;281:90-8.

95. Bell PE, Hossack KE, Gabow PA, Durr JA, Johnson AM, Schrier RW. Hypertension in autosomal dominant polycystic kidney disease. Kidney Int. 1988;34:683-90.

96. Loghman-Adham M, Soto CE, Inagami T, Cassis L. The intrarenal renin-angiotensin system in autosomal dominant polycystic kidney disease. Am J Physiol Renal Physiol. 2004;287:F775-88.

97. Xue C, Zhou C, Dai B, Yu S, Xu C, Mao Z, et al. Antihypertensive treatments in adult autosomal dominant polycystic kidney disease: network meta-analysis of the randomized controlled trials. Oncotarget. 2015 Dec 2.

98. Nutahara K, Higashihara E, Horie S, Kamura K, Tsuchiya K, Mochizuki T, et al. Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease. Nephron Clin Pract. 2005;99:c18-23.

99. Zafar I, Tao Y, Fulk S, McFann K, Schrier RW, Edelstein CL. Effect of statin and angiotensin-converting enzyme inhibition on structural and hemodynamic alterations in autosomal dominant polycystic kidney disease model. Am J Physiol Renal Physiol. 2007;293:F854-9.

100. Jafar TH, Stark PC, Schmid CH, Strandgaard S, Kamper AL, Maschio G, et al. The effect of angiotensin-converting-enzyme inhibitors on progression of advanced polycystic kidney disease. Kidney Int. 2005;67:265-71.

101. Kanno Y, Suzuki H, Okada H, Takenaka T, Saruta T. Calcium channel blockers versus ACE inhibitors as antihypertensives in polycystic kidney disease. QJM. 1996;89:65-70.

102. Ruggenenti P, Perna A, Gherardi G, Benini R, Remuzzi G. Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. Am J Kidney Dis. 2000;35:1155-65.

103. Ecder T, Chapman AB, Brosnahan GM, Edelstein CL, Johnson AM, Schrier RW. Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis. 2000;35:427-32.

104. Ecder T, Edelstein CL, Fick-Brosnahan GM, Johnson AM, Chapman AB, Gabow PA, et al. Diuretics versus angiotensin-converting enzyme inhibitors in autosomal dominant polycystic kidney disease. Am J Nephrol. 2001;21:98-103.

105. van Dijk MA, Breuning MH, Duizer R, van Es LA, Westendorp RG. No effect of enalapril on progression in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2003;18:2314-20.